tiprankstipranks
AC Immune Announces Promising Safety Data for Down Syndrome Therapy
Company Announcements

AC Immune Announces Promising Safety Data for Down Syndrome Therapy

Story Highlights

Pick the best stocks and maximize your portfolio:

AC Immune SA ( (ACIU) ) has shared an announcement.

AC Immune SA announced positive interim safety data from its Phase 1b/2 ABATE trial of ACI-24.060 for individuals with Down syndrome, highlighting the therapy’s safety and tolerability. The findings are promising as no serious adverse events or amyloid-related imaging abnormalities were observed, encouraging the expansion to a high-dose cohort. The trial aims to address the early stages of Alzheimer’s disease in this population, with ongoing recruitment in the U.S., U.K., and Spain.

More about AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, utilizing its SupraAntigen® and Morphomer® platforms. The company is recognized for its extensive pipeline of therapeutic and diagnostic programs and strategic partnerships with leading pharmaceutical firms.

YTD Price Performance: -37.20%

Average Trading Volume: 113,182

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $313M

For an in-depth examination of ACIU stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAC Immune announces interim safety, tolerability data from ABATE Phase 1b/2
TipRanks Auto-Generated NewsdeskAC Immune Q3 2024: Strong Progress and Financial Turnaround
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App